{"id":963503,"date":"2026-05-15T10:19:02","date_gmt":"2026-05-15T14:19:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/"},"modified":"2026-05-15T10:19:02","modified_gmt":"2026-05-15T14:19:02","slug":"whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/","title":{"rendered":"Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\">MORRISTOWN, N.J.<\/span>, <span class=\"legendSpanClass\">May 15, 2026<\/span> \/PRNewswire\/ &#8212; Whitehawk Therapeutics, Inc.\u00a0(Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC)\u00a0cancer treatments,\u00a0today announced Dave Lennon, PhD, President and CEO, will participate in a virtual fireside chat as part of the 2026 Stifel Virtual Targeted Oncology Forum on Tuesday, May 19, 2026, at 3 PM ET.<\/p>\n<p>A live webcast of the event can be accessed by visiting the Whitehawk Therapeutics IR\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4689658-1&amp;h=3602151948&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4100255-1%26h%3D2471710764%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3955997-1%2526h%253D1403846191%2526u%253Dhttps%25253A%25252F%25252Fir.aadibio.com%25252Fevent-calendar%2526a%253Dwebsite%26a%3Dwebsite&amp;a=website\" target=\"_blank\" rel=\"nofollow\">website<\/a>\u00a0and will be available for replay for approximately 30 days following the event.<\/p>\n<p>\n        <b>About Whitehawk Therapeutics\u00a0<br \/><\/b>Whitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk&#8217;s advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4689658-1&amp;h=2355764400&amp;u=https%3A%2F%2Fwww.whitehawktx.com%2F&amp;a=www.whitehawktx.com\" target=\"_blank\" rel=\"nofollow\">www.whitehawktx.com<\/a>\u00a0and connect with us on LinkedIn.<\/p>\n<p>\n        <b>Contact:<br \/><\/b><br \/>\n        <a href=\"mailto:IR@whitehawktx.com\" target=\"_blank\" rel=\"nofollow\">IR@whitehawktx.com<\/a>\n      <\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder9041\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/2644441\/Whitehawk_Therapeutics_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/2644441\/Whitehawk_Therapeutics_Logo.jpg\" title=\"Whitehawk Therapeutics, Inc. logo (PRNewsfoto\/Whitehawk Therapeutics, Inc.)\" alt=\"Whitehawk Therapeutics, Inc. logo (PRNewsfoto\/Whitehawk Therapeutics, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=LA60642&amp;sd=2026-05-15\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum-302773247.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum-302773247.html<\/a><\/p>\n<p>SOURCE Whitehawk Therapeutics, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA60642&amp;Transmission_Id=202605150800PR_NEWS_USPR_____LA60642&amp;DateId=20260515\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire MORRISTOWN, N.J., May 15, 2026 \/PRNewswire\/ &#8212; Whitehawk Therapeutics, Inc.\u00a0(Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC)\u00a0cancer treatments,\u00a0today announced Dave Lennon, PhD, President and CEO, will participate in a virtual fireside chat as part of the 2026 Stifel Virtual Targeted Oncology Forum on Tuesday, May 19, 2026, at 3 PM ET. A live webcast of the event can be accessed by visiting the Whitehawk Therapeutics IR\u00a0website\u00a0and will be available for replay for approximately 30 days following the event. About Whitehawk Therapeutics\u00a0Whitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk&#8217;s advanced three-asset &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-963503","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire MORRISTOWN, N.J., May 15, 2026 \/PRNewswire\/ &#8212; Whitehawk Therapeutics, Inc.\u00a0(Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC)\u00a0cancer treatments,\u00a0today announced Dave Lennon, PhD, President and CEO, will participate in a virtual fireside chat as part of the 2026 Stifel Virtual Targeted Oncology Forum on Tuesday, May 19, 2026, at 3 PM ET. A live webcast of the event can be accessed by visiting the Whitehawk Therapeutics IR\u00a0website\u00a0and will be available for replay for approximately 30 days following the event. About Whitehawk Therapeutics\u00a0Whitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk&#8217;s advanced three-asset &hellip; Continue reading &quot;Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-15T14:19:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2644441\/Whitehawk_Therapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum\",\"datePublished\":\"2026-05-15T14:19:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\\\/\"},\"wordCount\":205,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2644441\\\/Whitehawk_Therapeutics_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\\\/\",\"name\":\"Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2644441\\\/Whitehawk_Therapeutics_Logo.jpg\",\"datePublished\":\"2026-05-15T14:19:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2644441\\\/Whitehawk_Therapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2644441\\\/Whitehawk_Therapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/","og_locale":"en_US","og_type":"article","og_title":"Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum - Market Newsdesk","og_description":"PR Newswire MORRISTOWN, N.J., May 15, 2026 \/PRNewswire\/ &#8212; Whitehawk Therapeutics, Inc.\u00a0(Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC)\u00a0cancer treatments,\u00a0today announced Dave Lennon, PhD, President and CEO, will participate in a virtual fireside chat as part of the 2026 Stifel Virtual Targeted Oncology Forum on Tuesday, May 19, 2026, at 3 PM ET. A live webcast of the event can be accessed by visiting the Whitehawk Therapeutics IR\u00a0website\u00a0and will be available for replay for approximately 30 days following the event. About Whitehawk Therapeutics\u00a0Whitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk&#8217;s advanced three-asset &hellip; Continue reading \"Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-15T14:19:02+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2644441\/Whitehawk_Therapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum","datePublished":"2026-05-15T14:19:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/"},"wordCount":205,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2644441\/Whitehawk_Therapeutics_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/","name":"Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2644441\/Whitehawk_Therapeutics_Logo.jpg","datePublished":"2026-05-15T14:19:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2644441\/Whitehawk_Therapeutics_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2644441\/Whitehawk_Therapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/whitehawk-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/963503","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=963503"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/963503\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=963503"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=963503"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=963503"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}